TickerFacts.

Company research / CLDX

Celldex Therapeutics, Inc. (CLDX)

Build a valuation ↗↓ Download CSV

CIK 0000744218 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Celldex Therapeutics, Inc. reported revenue of $1.54M. Revenue fell 78.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $158.0K.

Key ratios (year ended 2025-12-31)

87.1%
Gross margin (computed)
n/m
Operating margin
n/m
Net margin
-49.1%
Return on year-end equity
-78.0%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-22

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$158.0K$1.54M$7.02M$6.88M$2.36M$4.65M$7.42M$3.57M$9.54M$12.74M$6.79M
Cost of Revenuen/a$200.0K$200.0K$300.0K$100.0K$100.0K$200.0K$100.0K$700.0K$700.0K$1.60M
Gross Profit (computed)n/a$1.34Mn/an/an/an/an/an/a$8.84M$12.04M$5.19M
R&D Expense$278.81M$245.07M$163.55M$118.01M$82.26M$53.31M$42.53M$42.67M$66.45M$96.17M$102.73M
Operating Income-$325.83M-$287.37M-$195.08M-$154.54M-$115.23M-$71.24M-$63.35M-$55.03M-$156.44M-$121.53M-$132.92M
Depreciation & Amortization$3.40M$3.38M$3.18M$3.01M$2.90M$3.07M$3.93M$4.86M$3.58M$4.41M$3.10M
EBITDA-$322.43M-$283.99M-$191.90M-$151.53M-$112.34M-$68.17M-$59.42M-$50.17M-$152.86M-$117.11M-$129.82M
Net Income-$300.55M-$258.76M-$157.86M-$141.43Mn/an/an/an/an/an/an/a
EPS (Diluted)n/a-$3.90-$2.45-$2.92-$2.40-$1.64-$2.02-$3.51n/an/an/a
Total Assets$782.35M$582.98M$792.34M$465.63M$352.74M$444.65M$235.84M$122.93M$155.81M$315.62M$383.36M
Total Liabilities$67.78M$55.82M$45.34M$36.46M$26.53M$25.18M$26.48M$28.91M$31.75M$79.25M$117.93M
Shareholders' Equity$714.56M$527.16M$747.00M$429.17M$326.20M$419.48M$209.36M$94.03M$124.06M$236.37M$265.43M
Cash & Equivalents$47.45M$28.87M$28.36M$34.81M$29.43M$39.14M$43.84M$11.23M$24.31M$40.29M$42.46M
Operating Cash Flow-$235.57M-$210.94M-$157.78M-$107.29M-$103.73M-$60.91M-$40.40M-$46.41M-$75.23M-$99.93M-$113.04M
Capital Expenditures$6.54M$2.71M$1.92M$1.82M$1.83M$1.25M$1.55M$731.0K$813.0K$1.79M$2.75M
Free Cash Flow-$242.10M-$213.66M-$159.70M-$109.11M-$105.56M-$62.16M-$41.96M-$47.15M-$76.05M-$101.72M-$115.79M
Shares Outstanding78.50M66.55M66.37M55.88Mn/an/an/an/a11.96M9.23M120.52M
Weighted Average Diluted Sharesn/a66.42M64.39M48.45M46.9K42.9K29.6K14.5Kn/an/an/a
EPS (Basic)n/a-$3.90-$2.45-$2.92-$2.40-$1.64-$2.02-$3.51n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView